MetaVia Inc. Cash Flow Conversion Efficiency
MetaVia Inc. cash flow conversion efficiency. Based on the latest financial reports, MetaVia Inc. (MTVA) has a cash flow conversion efficiency ratio of -0.551x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.76 Million) by net assets ($6.82 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of MetaVia Inc. (2014–2025)
Cash flow conversion efficiency of MetaVia Inc. from 2014 to 2025. This chart illustrates how MetaVia Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View MTVA share price today for real-time trading data and today's change.
MetaVia Inc. Cash Flow Conversion Ratio Explained
MetaVia Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
MetaVia Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MetaVia Inc. ranked by their cash flow conversion efficiency. Also see MetaVia Inc. (MTVA) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Maisons du Monde SAS
PA:MDM
|
-0.014x |
|
B.A.G Films and Media Limited
NSE:BAGFILMS
|
-0.017x |
|
Mont Royal Resources Ltd
AU:MRZ
|
-0.018x |
|
GCP Infrastructure Investments Limited
LSE:GCP
|
0.039x |
|
Brunner Investment Trust
LSE:BUT
|
0.004x |
|
Constellation Resources Ltd
AU:CR1
|
-1.081x |
|
Asuransi Bintang Tbk
JK:ASBI
|
-0.011x |
|
KAP AG
F:IUR
|
0.004x |
Annual Cash Flow Conversion Efficiency for MetaVia Inc. (2014–2025)
The table below shows the annual cash flow conversion efficiency of MetaVia Inc. from 2014 to 2025. Review MTVA financial flexibility score to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.33 Million | $-15.70 Million | -2.944x | +5.50% |
| 2024-12-31 | $7.93 Million | $-24.71 Million | -3.116x | -381.38% |
| 2023-12-31 | $16.68 Million | $-10.80 Million | -0.647x | -20.19% |
| 2022-12-31 | $21.75 Million | $-11.71 Million | -0.538x | +48.06% |
| 2021-12-31 | $14.60 Million | $-15.13 Million | -1.037x | +30.62% |
| 2020-12-31 | $7.20 Million | $-10.76 Million | -1.494x | -160.96% |
| 2019-12-31 | $12.29 Million | $-7.04 Million | -0.573x | -152.65% |
| 2018-12-31 | $-13.29 Million | $-14.45 Million | 1.088x | +115.93% |
| 2017-12-31 | $3.94 Million | $-26.90 Million | -6.826x | -1175.31% |
| 2016-12-31 | $20.63 Million | $-11.04 Million | -0.535x | -221.96% |
| 2015-12-31 | $-12.38 Million | $-5.43 Million | 0.439x | +19.50% |
| 2014-12-31 | $-531.00K | $-195.00K | 0.367x | -- |
About MetaVia Inc.
MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as … Read more